{
    "Clinical Trial ID": "NCT01572727",
    "Intervention": [
        "INTERVENTION 1: ",
        "  BKM120 and Paclitaxel",
        "  Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received study drug plus paclitaxel",
        "INTERVENTION 2: ",
        "  Placebo and Paclitaxel",
        "  Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received placebo plus paclitaxel"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Breast cancer that is locally advanced or metastatic",
        "  HER2 negative disease, and a known hormone receptor status - ER/PgR (common breast cancer classification tests)",
        "  A tumor sample must be shipped to a central lab for identification of biomarkers (PI3K activation status) before randomization",
        "  Adequate bone marrow and organ function",
        "  Measurable or non-measurable disease",
        "Exclusion Criteria:",
        "  Prior chemotherapy for locally advanced or metastatic disease",
        "  Previous treatment with PI3K or AKT inhibitors",
        "  Patient has symptomatic CNS metastases",
        "  Concurrent malignancy or malignancy within 3 years of study enrollment",
        "  Hematopoietic colony-stimulating growth factors or radiation within 2-4 weeks prior to starting study drug",
        "  Increasing or chronic treatment (> 5 days) with corticosteroids or another immunosuppressive agent",
        "  Active heart (cardiac) disease as defined in the protocol",
        "  Known hypersensitivity or contraindications to use paclitaxel",
        "  Pregnant or nursing (lactating) woman",
        "  Certain scores on an anxiety and depression mood questionaire given at screening",
        "  Other protocol defined criteria may apply"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Progression-free Survival (PFS)Assessed by Local Investigator's Assessment (Phase ll)",
        "  PFS was defined as the time from the date of randomization to the date of the event, defined as the first radiologically documented disease progression or death due to any cause. Progression was defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.",
        "  Time frame: Every 8 weeks from randomization until disease progression up to 10 months after futility was analyzed",
        "Results 1: ",
        "  Arm/Group Title: BKM120 and Paclitaxel",
        "  Arm/Group Description: Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received study drug plus paclitaxel",
        "  Overall Number of Participants Analyzed: 168",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  8.0        (7.2 to 9.2)",
        "Results 2: ",
        "  Arm/Group Title: Placebo and Paclitaxel",
        "  Arm/Group Description: Adult females with histologically confirmed, inoperable, locally advanced or metastatic HER2- BC who received placebo plus paclitaxel",
        "  Overall Number of Participants Analyzed: 170",
        "  Median (95% Confidence Interval)",
        "  Unit of Measure: Months  9.2        (7.3 to 11.0)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 61/202 (30.20%)",
        "  FEBRILE NEUTROPENIA 1/202 (0.50%)",
        "  LEUKOPENIA 0/202 (0.00%)",
        "  NEUTROPENIA 2/202 (0.99%)",
        "  CARDIAC FAILURE CONGESTIVE 0/202 (0.00%)",
        "  CARDIO-RESPIRATORY ARREST 1/202 (0.50%)",
        "  PERICARDIAL EFFUSION 1/202 (0.50%)",
        "  CATARACT 1/202 (0.50%)",
        "  OPTIC NEUROPATHY 0/202 (0.00%)",
        "  ABDOMINAL PAIN 0/202 (0.00%)",
        "  CONSTIPATION 0/202 (0.00%)",
        "  DIARRHOEA 5/202 (2.48%)",
        "Adverse Events 2:",
        "  Total: 42/201 (20.90%)",
        "  FEBRILE NEUTROPENIA 0/201 (0.00%)",
        "  LEUKOPENIA 1/201 (0.50%)",
        "  NEUTROPENIA 0/201 (0.00%)",
        "  CARDIAC FAILURE CONGESTIVE 1/201 (0.50%)",
        "  CARDIO-RESPIRATORY ARREST 0/201 (0.00%)",
        "  PERICARDIAL EFFUSION 0/201 (0.00%)",
        "  CATARACT 1/201 (0.50%)",
        "  OPTIC NEUROPATHY 1/201 (0.50%)",
        "  ABDOMINAL PAIN 1/201 (0.50%)",
        "  CONSTIPATION 1/201 (0.50%)",
        "  DIARRHOEA 3/201 (1.49%)"
    ]
}